Article
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
Breast cancer research and treatment - 1 Jan 2016
Barac Ana, Lynce Filipa, Smith Karen L, Mete Mihriye, Shara Nawar M, Asch Federico M, Nardacci Madeline P, Wray Lynette, Herbolsheimer Pia, Nunes Raquel A, Swain Sandra M, Warren Robert, Peshkin Beth N, Isaacs Claudine
Abstract excerpt
Animal data suggest that defects in BRCA1/2 genes significantly increase the risk of heart failure and mortality in mice exposed to doxorubicine. Women with BRCA1/2 mutations who develop breast cancer (BC) may receive anthracyclines but their risk of cardiac dysfunction has not been investigated. Our study tested the hypothesis that women with history of BRCA1/2 mutation-associated BC treated with anthracyclines...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.